Relay Therapeutics, Inc. Share Price & Technical Analysis
RLAY · $13.53 (-0.95%)
Healthcare / Biotechnology
$13.53
-0.95%
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clini…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
5% return in May, -5% avg return in past 3 year May month.
60% return in 2026, 6% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -8% | 34% | 0% | 29% | 5% | – | – | – | – | – | – | – | 60% |
| 25 | 7% | -21% | -24% | 27% | -9% | 17% | 0% | 3% | 44% | 37% | 13% | 9% | 103% |
| 24 | -15% | 8% | -19% | -22% | -2% | 0% | 28% | -16% | 4% | -20% | -18% | -15% | -85% |
| 23 | 42% | -25% | 2% | -31% | -3% | 15% | 0% | -18% | -18% | -21% | 20% | 39% | 0% |
| 22 | -28% | 3% | 26% | -20% | -31% | 2% | 14% | 23% | -1% | -2% | -19% | -19% | -53% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.42B
P/E ratio
—
52W high
$17.32
52W low
$2.83
Volume
53,55,352
Beta
1.75
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Relay Therapeutics, Inc. share price today?
- Relay Therapeutics, Inc. (RLAY) last traded around $13.53 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RLAY have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RLAY. Download the app for real-time alerts.
- How can I analyze Relay Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.